Transitioning to Biosimilars: Considerations for Providers and Payers

EP: 1.Utilizing Recently Approved Biosimilars in Clinical Practice

Now Viewing

EP: 2.Transitioning to Biosimilars: Considerations for Providers and Payers

EP: 3.Navigating Challenges Associated with Biosimilars Across Various Disease States

EP: 4.Provider Acceptance Driving Confidence in Biosimilar Therapy

EP: 5.Decision-Making Process Surrounding Biosimilar Implementation

EP: 6.Biosimilar Administration Considerations Impacting Patient Experience

EP: 7.Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience

EP: 8.Switching Patients from Reference Product to Biosimilar

EP: 9.Defining Interchangeability and Switching in Biologics

EP: 10.Evolution of Auto-Substitution in Biosimilar Landscape

EP: 11.An Overview of Biosimilar Extrapolation During FDA Approval

EP: 12.Harnessing Indication-Specific Data on Biosimilars

EP: 13.Cost Savings Related to Biosimilars

EP: 14.Payers and PBMs Impacted by Biosimilar Integration

EP: 15.Payer Support Driving Lowering of Biosimilar-Related Health Care Costs

EP: 16.Patient Conversations: Managing Patient Expectations Regarding Biosimilars

EP: 17.Key Points of Emphasis Regarding Biosimilar Integration

This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD.

Haumschild asked Brogan about the key opportunities provided by biosimilars for inflammatory conditions, specifically seeking her insights on opportunities around adalimumab (Humira) biosimilar access and use for providers and payers.

Brogan responded that biosimilars provide cost savings opportunities through competition, which could free up health care dollars for other needed treatments. The VOLTAIRE trials with adalimumab biosimilar BI 695501 (adalimumab-adbm, Cyltezo; Boehringer Ingelheim) included Crohn disease patients, providing indication-specific data to reassure providers. From the payer perspective, adalimumab biosimilar competition allows price negotiations and access to discounts off the originator price. Payers will need to adapt formularies and provide education to ensure successful adoption.

Haumschild agreed cost savings would be beneficial, but noted provider concerns around immunogenicity, switching limits, and product differences that require thoughtful education so that patients understand without getting overwhelmed.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.